These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 11284438)

  • 21. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
    Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist.
    Zocchi C; Ongini E; Conti A; Monopoli A; Negretti A; Baraldi PG; Dionisotti S
    J Pharmacol Exp Ther; 1996 Feb; 276(2):398-404. PubMed ID: 8632302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular pharmacology of the A2A adenosine receptor antagonist, SCH 58261, in the rat.
    Monopoli A; Casati C; Lozza G; Forlani A; Ongini E
    J Pharmacol Exp Ther; 1998 Apr; 285(1):9-15. PubMed ID: 9535988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
    Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
    Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
    Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
    Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Mela F; Millan MJ; Brocco M; Morari M
    Neuropharmacology; 2010 Feb; 58(2):528-36. PubMed ID: 19733554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression.
    Morelli M; Fenu S; Pinna A; Di Chiara G
    J Pharmacol Exp Ther; 1992 Jan; 260(1):402-8. PubMed ID: 1346165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does adenosine receptor blockade mediate caffeine-induced rotational behavior?
    Garrett BE; Holtzman SG
    J Pharmacol Exp Ther; 1995 Jul; 274(1):207-14. PubMed ID: 7616401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours.
    Lane EL; Cheetham SC; Jenner P
    Eur J Neurosci; 2005 Jan; 21(1):179-86. PubMed ID: 15654855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression.
    Hodgson RA; Bertorelli R; Varty GB; Lachowicz JE; Forlani A; Fredduzzi S; Cohen-Williams ME; Higgins GA; Impagnatiello F; Nicolussi E; Parra LE; Foster C; Zhai Y; Neustadt BR; Stamford AW; Parker EM; Reggiani A; Hunter JC
    J Pharmacol Exp Ther; 2009 Jul; 330(1):294-303. PubMed ID: 19332567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
    Lane EL; Cheetham SC; Jenner P
    Exp Neurol; 2006 Feb; 197(2):284-90. PubMed ID: 16005456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New adenosine A2A receptor antagonists: actions on Parkinson's disease models.
    Pinna A; Volpini R; Cristalli G; Morelli M
    Eur J Pharmacol; 2005 Apr; 512(2-3):157-64. PubMed ID: 15840400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats.
    Bové J; Marin C; Bonastre M; Tolosa E
    Synapse; 2002 Dec; 46(4):251-7. PubMed ID: 12373740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.
    Tanganelli S; Sandager Nielsen K; Ferraro L; Antonelli T; Kehr J; Franco R; Ferré S; Agnati LF; Fuxe K; Scheel-Krüger J
    Parkinsonism Relat Disord; 2004 Jul; 10(5):273-80. PubMed ID: 15196505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.
    Dionisotti S; Ongini E; Zocchi C; Kull B; Arslan G; Fredholm BB
    Br J Pharmacol; 1997 Jun; 121(3):353-60. PubMed ID: 9179373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Ann Neurol; 1998 Apr; 43(4):507-13. PubMed ID: 9546333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig.
    Moses D; Gross A; Finberg JP
    Neuropharmacology; 2004 Jul; 47(1):72-80. PubMed ID: 15165835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.